of a given patient's FN risk depends on knowledge of key FN risk factors. The performance of currently available FN prediction models in the literature indicated room for improvement in clinical FN risk prediction. 18 , 19 Thus, the objective of this
Search Results
A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora
Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
summarized and compared between those with and without SREs using the Fisher exact test for the categorical risk factors and the Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute
Increasing Incidence of Intrahepatic Cholangiocarcinoma and its Relationship to Chronic Viral Hepatitis
Kwang-Yu Chang, Jang-Yang Chang, and Yun Yen
– 281 . 9 Su CH Shyr YM Lui WY P’Eng FK . Hepatolithiasis associated with cholangiocarcinoma . Br J Surg 1997 ; 84 : 969 – 973 . 10 Ahrens W Timmer A Vyberg M . Risk factors for extrahepatic biliary tract carcinoma in men
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
Mikkael A. Sekeres
be an overestimate, a rate of 60,000 people likely underestimates the impact of the disease. Risk Factors for Developing MDS The greatest risk factor for developing MDS is advanced age, with yearly incidence rates increasing 10-fold for
NCCN Task Force Report: Bone Health and Cancer Care
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
critical issue for all cancer patients, regardless of other risk factors, and should be incorporated into comprehensive cancer care. An American Society of Clinical Oncology (ASCO) Task Force statement on bone health in women with breast cancer noted, “Many
Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study
Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow
) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy
Update on Guidelines for the Prevention of Cancer-Associated Thrombosis
Amro Elshoury, Jordan K. Schaefer, Ming Y. Lim, Deidre P. Skalla, and Michael B. Streiff
conditions is still referred to as Trousseau syndrome. Patients with cancer constitute 15% to 20% of the patients diagnosed with venous thromboembolism (VTE). 3 Depending on the type of tumor, cancer therapy, and presence of other risk factors, 1% to 25% of
Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry
Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative
of LR (whether unifocal or multicentric), independent risk factors for LR, and 2-year DFS and OS rates. DFS was defined as patients who were alive without evidence of local or distant recurrence. OS was defined as those who were alive with or
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group
Platinum Study ( P =.30), and other clinical and sociodemographic characteristics ( supplemental eTable 1 , available with this article at JNCCN.org ). Data on the prevalence of metabolic syndrome and its risk factors in this cohort have been previously
Risk Factors for the Assessment of Patients with Pulmonary Embolism
John Fanikos and Samuel Z. Goldhaber
: a 25 year population based study . Arch Intern Med 1998 ; 15 : 585 – 593 . 5. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern Med
